Ekso Bionics (NASDAQ:EKSO) Price Target Lowered to $9.00 at HC Wainwright

Ekso Bionics (NASDAQ:EKSO) had its price objective dropped by research analysts at HC Wainwright from $10.00 to $9.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright also issued estimates for Ekso Bionics’ FY2026 earnings at $0.02 EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.43 EPS.

Separately, StockNews.com initiated coverage on Ekso Bionics in a research report on Saturday, October 26th. They set a “hold” rating on the stock.

Ekso Bionics Stock Down 2.9 %

Shares of EKSO opened at $0.93 on Tuesday. Ekso Bionics has a 1 year low of $0.83 and a 1 year high of $3.13. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.42 and a quick ratio of 1.77. The business’s 50 day simple moving average is $1.11 and its 200-day simple moving average is $1.15. The stock has a market capitalization of $16.94 million, a price-to-earnings ratio of -0.96 and a beta of 1.45.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The business had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. During the same quarter in the previous year, the company posted ($0.24) earnings per share. As a group, equities analysts expect that Ekso Bionics will post -0.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC lifted its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the period. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. Institutional investors own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.